PMR - PowerShares Dynamic Retail ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
33.9725
+0.3725 (+1.1086%)
At close: 3:32PM EDT
Stock chart is not supported by your current browser
Previous Close33.6000
Open33.7450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range33.7450 - 33.9725
52 Week Range32.0000 - 38.8600
Volume1,974
Avg. Volume1,293
Net Assets13.61M
NAV34.02
PE Ratio (TTM)N/A
Yield1.16%
YTD Return-4.74%
Beta (3y)0.53
Expense Ratio (net)0.63%
Inception Date2005-10-26
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    The World Health Organization Selects Tivanisiran as the International Nonproprietary Name for SYL1001

    Sylentis, a Pharmaceutical Company of PharmaMar Group (PHM), pioneer in the development of new compounds based on genetic silencing technology through RNA interference (RNAi), has announced that the World Health Organization (WHO) has given its approval, as disclosed in paragraph 7 of the International Nonproprietary Name in Pharmaceutical Substances (INN) selection procedure. This entails the designation of tivanisiran as the chosen INN for the compound SYL1001.

  • PR Newswire4 days ago

    Final Data on Phase I/II in Small-cell Lung Cancer with Zepsyre® Presented at the IASCLC 18th World Conference on Lung Cancer in Japan

    PharmaMar (PHM), a biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs, has presented updated data from Zepsyre Phase I/II trials in relapse small cell lung cancer in an oral presentation at the International Association for the Study of Lung Cancer (IASLC), at 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. As Dr Calvo said, "What we have seen is an exceptional Progression Free Survival benefit, and in patients treated with PM1183 in combination with doxorubicin we saw 21 of 27 patients experience some tumor reduction.

  • PR Newswire12 days ago

    PharmaMar Will Present Final Data on PM1183 During the 18th World Lung Conference in Japan

    PharmaMar (PHM) will present the final efficacy and safety data obtained from the Phase I/II trial combining PM1183 (lurbinectedin) with doxorubicin in relapsed small-cell lung cancer during a 'Research Perspectives' oral session, on October 16th (abstract ID9249). This study shows that patients treated with PM1183 in combination with doxorubicin (Phase I/II clinical trial) reached a progression free survival (5.3 months) which compares favorably with historical data of topotecan as a single agent (the PFS varies between 3.1 and 3.5 months). The objective response rate, a 37% is observed in patients in a combination between PM1183 and doxorubicin compares to historical data of topotecan in relapsed disease of between 17% and 24%.

  • PR Newswire18 days ago

    PharmaMar Submits the Marketing Authorisation Application for Aplidin® in Switzerland

    PharmaMar (PHM) announces submission of the Marketing Authorisation Application to the Swiss Agency for Therapeutic Products (Swissmedic) for Aplidin® for the treatment of patients with multiple myeloma.

  • Retail ETFs in Focus on Early Holiday Sales Forecast
    Zacks27 days ago

    Retail ETFs in Focus on Early Holiday Sales Forecast

    Early holiday sales forecasts point to healthier sales.

  • PR Newswire27 days ago

    PharmaMar: Sylentis Presents New Data on a New Eye Drop siRNA for the Treatment of Retinal Diseases Avoiding Intraocular Injections

    MADRID , September 25, 2017 /PRNewswire/ -- This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect ...

  • PR Newswirelast month

    PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors

    With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (PHM) announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors. After its preclinical phase, where the compound has demonstrated its activity in solid tumors in animal models, this Phase I clinical study has the primary objective of identifying the optimal dose for the administration of PM14 in patients with advanced solid tumors.

  • PR Newswirelast month

    PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors

    With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (PHM) announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors. After its preclinical phase, where the compound has demonstrated its activity in solid tumors in animal models, this Phase I clinical study has the primary objective of identifying the optimal dose for the administration of PM14 in patients with advanced solid tumors.

  • Market Realistlast month

    A Look at Regency Centers’ Dividend Yield

    Retail REIT Regency Centers (REG) saw its revenue grow 8% in 2016, compared with 6% in 2015. The growth was driven by minimum rent, recoveries from tenants, and other income.…

  • PR Newswirelast month

    New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer

    The abstract #1529 'Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)' shows an objective response rate of 36% when PM1183 is used as a single agent. The results become of special relevance if it is taken into account that microcitic lung cancer is the most aggressive type of lung cancer for which only one treatment exists, topotecan, approved more than 15 years ago in advanced and relapsed illness. This drug shows a response rate that varies between 17% and 24%.

  • PR Newswirelast month

    New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer

    The abstract #1529 'Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)' shows an objective response rate of 36% when PM1183 is used as a single agent. The results become of special relevance if it is taken into account that microcitic lung cancer is the most aggressive type of lung cancer for which only one treatment exists, topotecan, approved more than 15 years ago in advanced and relapsed illness. This drug shows a response rate that varies between 17% and 24%.

  • PR Newswire2 months ago

    PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

    PharmaMar (PHM) will present the clinical data obtained from various clinical studies carried out with its antitumoral compounds of marine origin PM1183 and Yondelis®, during the European Society of Clinical Oncology (ESMO) that will be held from the 8th to the 12th of September in Madrid, Spain. The abstract #1529 titled "Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)" will be presented on September 11th. In this abstract, a cohort B will be presented using a new dosing regimen as compared to cohort A that was presented at the American Society of Clinical Oncology Annual Meeting in 2015.

  • PR Newswire2 months ago

    PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

    MADRID , August 31, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present the clinical data obtained from various clinical studies carried out with its antitumoral compounds of marine origin PM1183 and ...

  • PR Newswire2 months ago

    PharmaMar Starts a Quadruple Combination Study With Aplidin® for the Treatment of Multiple Myeloma

    PharmaMar (PHM) announced the start of a multicenter quadruple combination clinical study with Aplidin® (plitidepsina), along with other compounds for the treatment of multiple myeloma. The main objective of this study is to evaluate the recommended dose (RD), the efficacy of the combination along with the safety profile, evaluating potential response and resistance markers, amongst other parameters.

  • The 5 Top Retail ETFs
    Motley Fool4 months ago

    The 5 Top Retail ETFs

    This specialty has only a handful of ETFs. Find out which one makes sense for you.

  • PR Newswire4 months ago

    FDA Chooses Zepsyre™ (PM1183) from PharmaMar to Explore Potential Development for Pediatric Cancers

    The Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (ODAC) of the FDA, has invited PharmaMar to participate in this ODAC, giving a presentation to provide background information on Zepsyre™, positive clinical data obtained from phases I and II, in which a good tolerance and a good safety profile were observed, and to assess the potential role of this drug in pediatric cancers and hematological disorders. Zepsyre™ (PM1183), PharmaMar´s investigational drug, is one of the three products chosen by ODAC.

  • Benzinga4 months ago

    Winners And Losers From Amazon's Purchase Of Whole Foods

    When the dust finally settled on Amazon.com, Inc. (NASDAQ: AMZN )’s historic $13.7 billion buyout bid for Whole Foods Market, Inc. (NASDAQ: WFM ) on Friday, Whole Foods stock was up 29.1 percent on the ...

  • PR Newswire4 months ago

    PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre™

    MADRID , June 16, 2017 /PRNewswire/ -- PharmaMar ( MCE: PHM ) has announced that PM1183 (lurbinectedin), its third molecule of marine origin and analogue of Yondelis ® , will receive the trade name of ...

  • PR Newswire4 months ago

    PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers

    PharmaMar (PHM) has participated in the Annual Meeting of the American society of Clinical Oncology (ASCO) with new data with inhibitors of activated transcription, Yondelis® and lurbinectedin. The Company has presented various studies in different types of tumors, amongst which can be highlighted the results of the study of lurbinectedin in advanced endometrial cancer that showed this molecule is active both as a single agent and when given in combination with doxorubicin (Link to the abstract). According to Dr. Arturo Soto, Director of Clinical Development at the Oncology Business Unit at PharmaMar, "we are very pleased with the positive results obtained in endometrial cancer with lurbinectedin, both as a single agent as in combination with doxorubicin.

  • PR Newswire5 months ago

    Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome

    The pharmaceutical Company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational new drug, SYL1001 for the indication of dry eye syndrome. The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). The Company has received final, End-of-Phase II meeting minutes from the FDA.

  • Market Realist5 months ago

    Ulta Beauty Stock Reacted Positively to Stellar 1Q17 Results

    The stock of beauty retailer Ulta Beauty (ULTA) rose 3.2% to $302.40 on May 26, 2017, in reaction to its fiscal 1Q17 results and upgraded outlook for fiscal 2017.

  • Market Realist5 months ago

    What’s behind Costco’s EPS Beat in Fiscal 3Q17?

    Strong sales, driven by increased comps (comparables) mainly in the United States (SPY), drove Costco's EPS growth during the quarter.

  • PR Newswire5 months ago

    PharmaMar and Eczacıbaşı Sign a Licensing Agreement for Aplidin® in Turkey

    PharmaMar (PHM) has announced today a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in Turkey. Under the terms of the agreement, PharmaMar will receive an upfront payment as well as development milestones related to the health approval procedure of Aplidin® in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacıbaşı for commercial use.

  • PR Newswire5 months ago

    PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017

    MADRID, May 19, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis ® and lurbinectedin, during the 53 ...

  • Retail ETF Returns Reflect Industry Upheaval
    ETF.com5 months ago

    Retail ETF Returns Reflect Industry Upheaval

    Some 20 years ago, a low rumbling of change began to build in the retail industry. Remember when Amazon, despite losing billions of dollars a year, started to eat the market-share lunch of bookstores? There was clear disruption going on, but really in a small material way back then. However, there were those who saw the future, and extrapolated that what Amazon was doing to bookstores would happen across retail. Many scoffed.